Proceeds from the Alexandria Real Estate Equities-backed series B round will advance the company's development of progenitor cell-related medicines for hearing loss.
US-based drug developer Frequency Therapeutics closed a $42m series B round on Monday that included the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities.
Alexandria Venture Investments was joined by venture capital firm Taiwania Capital, which led the round, and Axil Capital, a VC fund spun out of investment banking firm Mizuho Securities.
Yonjin Capital, a subsidiary of holding group Yonjin Group, also took part in the round, along with Polaris Founders Capital, CoBro…
